Key Highlights

  • Merck KGaA agreed on October 19 to buy Silence Therapeutics for $20 per ADS in cash, roughly $1.3 billion.
  • The AI Infrastructure Partnership agreed in October 2025 to buy Aligned Data Centers at a valuation of roughly $40 billion.
  • Peoples Bancorp agreed on September 30 to buy Capital Bancorp in an all-stock deal of roughly $728.1 million.
  • There have been 253 US IPOs in 2026, against 350 in all of 2025.
  • General Motors reported a new $20 billion repurchase authorization on October 20.

Which M&A Deals and Capital Markets Events Are in Focus Today?

Healthcare M&A is anchored by Merck KGaA's $1.3 billion agreement for Silence Therapeutics (NASDAQ:SLN), a 130% premium. Data-center M&A is anchored by the $40 billion Aligned Data Centers deal, and bank consolidation by Peoples Bancorp (NASDAQ:PEBO) and its $728.1 million all-stock agreement for Capital Bancorp (NASDAQ:CBNK). The IPO pipeline shows 253 US debuts in 2026, with Anthropic reportedly able to begin marketing the week of November 9, and buybacks are with leadership from the $20 billion authorization at General Motors (NYSE:GM).

Healthcare M&A: What Does the Silence Therapeutics Buyout Reveal Roughly 2026?

Merck KGaA agreed on October 19 to buy Silence Therapeutics for $20 per ADS, a 130% premium to the preceding session close. the shares ended the session at $19.66 on October 22, roughly 1.7% below the offer, calculated. The central drug, divesiran, targets polycythemia vera, and closing is anticipated over the opening quarter of 2027.

One research firm estimated first-half 2026 biotech and drug M&A above $130 billion across over 30 deals of $1 billion or more, including Merck KGaA's $11.3 billion purchase of Bio-Techne (NASDAQ:TECH). Novartis (NYSE:NVS) reported its $12 billion Avidity deal a year ago, at a 46% premium. Gilead Sciences (NASDAQ:GILD) struck a deal worth as much as $1.87 billion with Vir Biotechnology (NASDAQ:VIR) on October 14.

Silence had $72.1 million of cash at June 30, then raised $175 million in August at $13.50 per ADS. Holders of roughly 14% of the vote already support the deal. Roche agreed a $15 billion antibody-drug conjugate pact with Hansoh on October 19, a licensing deal and not a buyout.

Data-Center M&A: Why Does the $40 Billion Aligned Deal Set the Pace?

The AI Infrastructure Partnership, whose members include Microsoft (NASDAQ:MSFT) and Nvidia (NASDAQ:NVDA), agreed in October 2025 to buy Aligned Data Centers at roughly $40 billion, with closing then anticipated in the opening six months of 2026. Aligned has over 5 gigawatts of operational and planned capacity across 50 campuses.

Capital has moved along the supply chain. Eaton (NYSE:ETN) agreed to buy Boyd Thermal for $9.5 billion, Alphabet (NASDAQ:GOOGL) agreed in December 2025 to buy Intersect Power for $4.75 billion, and Vertiv (NYSE:VRT) bought PurgeRite for $1 billion in cash. Reported 2025 deals of $1 billion or more add as much as roughly $65 billion, calculated.

Aligned had recently raised over $5 billion of primary equity and secured over $7 billion of new debt commitments. Microsoft added 31 data centers for the quarter ended in June, and Equinix lifted 2026 sales outlook to $10.21 billion to $10.29 billion.

Bank Consolidation: Which Regional Bank Deals Are Moving Through Approvals?

Banco Santander (NYSE:SAN) agreed on February 3 to buy Webster Financial for roughly $12.3 billion, which received Federal Reserve approval on August 4, and Webster shares were delisted on August 20. Peoples Bancorp agreed on September 30 to buy Capital Bancorp, with each share converting into 1.11 Peoples shares and closing anticipated in the opening six months of 2027.

First Hawaiian (NASDAQ:FHB) agreed on July 13 to buy TriCo Bancshares (NASDAQ:TCBK), which holds a special shareholder meeting on October 29. HomeTrust agreed on August 17 to buy a Virginia-based bank for roughly $448.1 million, with closing anticipated in early 2027.

Completed deals already show in results. Associated Banc-Corp disclosed third-quarter EPS of $0.76, or $0.81 not counting roughly $13 million of costs tied to the April 1 American National acquisition.

IPO Pipeline: Is a Single Deal Set to Reshape the Fourth Quarter?

There have been 253 US IPOs in 2026 against 350 in all of 2025. Lycia Therapeutics (NASDAQ:LYCA) is seeking $250 million with trading set for Friday, October 23, and no IPOs are scheduled for next week. Anthropic filed a confidential draft registration on June 1 and could begin marketing the week of November 9, with trading in advance of Thanksgiving on November 26, though the timetable could change.

Pullbacks are rising. Klook withdrew an estimated $400 million US IPO on October 16, and Oura postponed its debut over a approximately $15 billion valuation target. SpaceX raised a record $75 billion in June, the benchmark Anthropic is anticipated to match or beat.

Not counting two record debuts, over 100 stocks that went public in 2026 had a weighted-average loss of 4% as of early October. Two biotech IPOs priced at the midpoint of their ranges, at $18 on October 16 and $16 on October 15.

Buybacks: Which Companies Announced Authorizations After Earnings?

General Motors reported a multi-year $20 billion authorization on October 20, and the shares ended the session at $77.09 that day, down 6.84%. Shares outstanding declined to 849 million from 904 million at the end of 2025, roughly 6.1% lower, calculated. Columbia Banking System (NASDAQ:COLB) approved as much as $1.2 billion on October 22, and First BanCorp (NYSE:FBP) reported $350 million with a 25% dividend increase.

Not every program is new. RingCentral (NYSE:RNG) repurchased $18 million during the third quarter against roughly $94 million in the second, with roughly $309 million left under its authorization and no new program reported.

Authorizations are caps, so the more informative figure is what companies actually buy. First BanCorp repurchased $50.0 million at an average price of $28.67 in the quarter, and Columbia repurchased $199 million.

M&A and Capital Markets Compared: How Do the Deal Sizes Line Up?

Merck KGaA's $11.3 billion Bio-Techne deal is roughly 8.7 times the $1.3 billion Silence price, and Aligned's $40 billion is roughly 4.2 times Eaton's $9.5 billion Boyd Thermal deal, both calculated. Santander's $12.3 billion Webster agreement is roughly 16.9 times Peoples Bancorp's $728.1 million deal, and that deal is roughly 1.6 times HomeTrust's $448.1 million, additionally calculated.

General Motors' $20 billion authorization is roughly 16.7 times Columbia Banking's $1.2 billion, calculated. RingCentral's third-quarter buyback was roughly 80.9% below its second, calculated, and the 253 IPOs so far are roughly 72% of 2025's full-year count.

Which Upcoming Developments Matter for Lycia's First Trade, the October 29 TriCo Meeting and Anthropic's November Window?

Lycia is set to begin trading on Friday, October 23, the Federal Reserve meets on October 27 and 28, and TriCo shareholders meet on October 29. Anthropic could begin marketing the week of November 9, after a public filing at least 15 days in advance of the roadshow. Columbia Banking plans fourth-quarter repurchases of $150 million to $200 million, whereas Silence's shareholder vote and approvals run into the first quarter of 2027.